A recent study by the ICMR National Centre for Disease Informatics and Research warns of a 5.6% annual increase in Indian breast cancer cases, driven by various risk factors.

In this study, researchers aimed to determine whether younger BRCA1/2 carriers who undergo oophorectomy can receive menopausal hormone therapy without increasing their risk of breast cancer.

The field of cancer treatment saw a variety of advancements in 2025, from new dedicated centers to approved treatments to ...

Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.

The APP ordered a bilateral diagnostic mammogram and left breast ultrasound that revealed extremely dense breast tissue, a ...

Holiday family gatherings offer a great opportunity to create valuable new memories with our loved ones, and to share ...

A pioneering study has found that an individualized approach to breast cancer screening that assesses patients' risk, rather ...

Angelina Jolie has shockingly faced a torrent of callous online abuse after boldly baring the scars from her double ...

Mr. Sasse, a former senator from Nebraska, announced that he had received a diagnosis last week for Stage 4 pancreatic cancer ...

The Phase 3 AMPLITUDE trial led by UCL found that adding the PARP inhibitor niraparib to standard hormone therapy may slow progression of hormone-sensitive prostate cancer in men with DNA repair gene ...

The 50-year-old actress underwent a preventative double mastectomy in 2013 after learning she had the BRCA1 gene, which significantly increased her risk of breast and ovarian cancer, and she always ...

A new ICMR study finds breast cancer among the top three cancers affecting Indian women, linking higher risk to age, obesity, ...